View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Special Focus
  2. Covid-19
April 10, 2020

Covid-19: From the analysts

By Paul Dennis

NHS assesses risk of Covid-19 infection in rheumatology patients
Many patient groups are at an increased risk of infection due to the global Covid-19 pandemic, extending to rheumatology patients who have been prescribed immunosuppressant medication. Although rheumatology patients are not the most at-risk demographic, the coronavirus outbreak has presented these patients with medical and logistical difficulties that can jeopardise their treatment.

Covid-19 cases may have peaked in Italy while US and UK will see the worst yet
Italy appears to have reached a plateau in the number of new cases of Covid-19 in the past week, but the US and the UK have yet to reach the peak. Nonetheless, none of the countries are near to being done with the pandemic. GlobalData estimates that it will take an additional one- to two-month time of continued strict social distancing efforts post peak before new cases will decrease to near zero.

The use of biomarkers to propel Covid-19 trials
With the number of Covid-19 trials steadily increasing, most are including biomarkers to help speed up the trials and reduce the cost of drug development. Even with standard trials, biomarkers can help reduce trial times, verify a drug’s mechanism of action, guide subject and dose selection, and minimise patient safety risks.


Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy